Masimo (NASDAQ:MASI) Price Target Raised to $210.00 at Piper Sandler

Masimo (NASDAQ:MASI) had its target price lifted by Piper Sandler from $180.00 to $210.00 in a report released on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the medical equipment provider’s stock.

MASI has been the subject of several other research reports. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research boosted their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $175.67.

Masimo Stock Up 0.2 %

Shares of MASI opened at $170.97 on Wednesday. Masimo has a 52-week low of $101.61 and a 52-week high of $180.97. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $159.31 and a two-hundred day simple moving average of $134.19. The company has a market capitalization of $9.15 billion, a PE ratio of 117.91 and a beta of 1.01.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Masimo’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business earned $0.63 earnings per share. As a group, equities analysts forecast that Masimo will post 4.03 EPS for the current year.

Institutional Investors Weigh In On Masimo

Several large investors have recently added to or reduced their stakes in MASI. FMR LLC grew its stake in Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock worth $900,860,000 after purchasing an additional 1,970,883 shares in the last quarter. State Street Corp boosted its stake in shares of Masimo by 0.7% in the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock valued at $191,837,000 after buying an additional 10,179 shares during the period. Westfield Capital Management Co. LP grew its position in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after buying an additional 262,370 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Masimo by 42.1% during the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after buying an additional 360,497 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after acquiring an additional 11,984 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.